Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (Boston)

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy.
Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, November 6, 2015, Abstract A68.